Jun 8 2011
Bio-Nucleonics, Inc., a life sciences Company, specializing in the development and manufacture of radiopharmaceuticals, medical devices and imaging agents, will be attending the Society of Nuclear Medicine (SNM) Annual Meeting, held in San Antonio, TX, June 4th through 8th, 2011.
The Company announced that it has resumed production of the cancer drug Strontium Chloride Sr-89 Injection USP ("Strontium-89"). Strontium-89 is an intravenously administered cancer drug that provides long lasting pain relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced stage breast, prostate or lung cancer.
Strontium-89 is preferentially absorbed in bone metastases, providing a long-term effect resulting in an enhanced quality-of-life. There are approximately 300,000 new cases per year in the U.S., an area of unmet medical need. It has been reported that there is a decrease in pain, an increase in physical activity and a reduction in the need for opiate analgesics, such as morphine, in up to 80% of patients.
President and Chief Executive Officer Roseanne Satz stated, "Our participation at SNM is crucial to meeting with our radiopharmacy customers and creating market awareness. The exposure and introductions gained from these industry conferences yield opportunities that advance our future growth. We are pleased to be able to fill the demand for this important drug which allows greater flexibility in pain management and improves patient quality-of-life."
ABOUT BIO-NUCLEONICS
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels